Biotech RadarJobs updated

COMPANY

Tango Therapeutics, Inc.

HQ: Boston, MA source · tangotx.com ↗ · New England

Clinical Phase 2

18 open jobs · last seen Oct 23, 2026 · 8 sources

Keywords: oncology tumors cancer Lung Cancer Non Small Cell Lung Cancer Lung Adenocarcinoma PDAC - Pancreatic Ductal Adenocarcinoma NSCLC RAS Mutation MTAP Deletion Pancreatic Cancer Metastatic Thoracic Cancer Glioma Glioblastoma Multiforme Malignant Glioma Non-Small Cell Adenocarcinoma Brain Tumor Breast Cancer Ovarian Cancer Pancreas Cancer Prostate Cancer BRCA1 Mutation BRCA-Mutated Ovarian Carcinoma BRCA-Associated Breast Carcinoma HRD Positive Advanced Ovarian Cancer TNG462 TNG260 RMC-9805 RMC-6236 TNG908 TNG456 TNG348

Location: Boston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Since the raise (Oct 23, 2025): 18 of 18 open jobs were first seen after it.

18Open jobs$225.0MRaised (2 yrs)6Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Vice President, Medical AffairsBoston, MAOct 19, 2026Oct 20, 2026
Associate Director, Statistical ProgrammingBoston, MAOct 19, 2026Oct 20, 2026
Associate Director, Operational ExcellenceBoston, MAOct 15, 2026Oct 16, 2026
Executive Director, Commercial Law/Commercial ContractsBoston, MAOct 2, 2026Oct 8, 2026
Director, Intellectual PropertyBoston, MAOct 2, 2026Oct 8, 2026

See all 18 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (18 open jobs at last check). source ↗
  2. Raise Private placement: $225M (total, as published), announced Oct 23, 2025. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 28, 2025 SEC Form D ↗
  3. Trial start Phase 1/Phase 2: Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients source ↗
  4. Trial start Phase 1/Phase 2: Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss source ↗
  5. Trial start Phase 1/Phase 2: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors source ↗
  6. Trial start Phase 1/Phase 2: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors source ↗
  7. Trial start Phase 1/Phase 2: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors source ↗
  8. Trial start Phase 1/Phase 2: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 18

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Vice President, Medical AffairsBoston, MAOct 19, 2026Oct 20, 2026Not stated
Associate Director, Statistical ProgrammingBoston, MAOct 19, 2026Oct 20, 2026Not stated
Associate Director, Operational ExcellenceBoston, MAOct 15, 2026Oct 16, 2026Not stated
Executive Director, Commercial Law/Commercial ContractsBoston, MAOct 2, 2026Oct 8, 2026Executive
Director, Intellectual PropertyBoston, MAOct 2, 2026Oct 8, 2026Senior
Senior Clinical Data ManagerBoston, MASep 18, 2026Oct 8, 2026Senior
Manager, GMP QualityBoston, MASep 14, 2026Oct 8, 2026Mid
Executive Director, Commercial Strategy & ExecutionBoston, MASep 8, 2026Oct 8, 2026Executive
Head of Marketing & SalesBoston, MASep 6, 2026Oct 8, 2026Executive
Head of Insights & AnalyticsBoston, MASep 6, 2026Oct 8, 2026Executive
Senior Vice President, Market AccessBoston, MASep 6, 2026Oct 8, 2026Executive
Associate Medical Director, PharmacovigilanceBoston, MAAug 21, 2026Oct 8, 2026Senior
Executive Director, Clinical DevelopmentBoston, MAAug 17, 2026Oct 8, 2026Executive
Director, BiostatisticsBoston, MAAug 12, 2026Oct 8, 2026Senior
Vice President, Clinical DevelopmentBoston, MAAug 12, 2026Oct 8, 2026Executive
Quality Management System LeadBoston, MAJul 23, 2026Oct 8, 2026Senior
Senior Director, Clinical DevelopmentBoston, MAJun 29, 2026Oct 8, 2026Senior
Director/Senior Director, GCP Quality AssuranceBoston, MAJun 16, 2026Oct 8, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $225.0M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT05732831Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsPhase 1/Phase 2RecruitingMay 26, 20232027-06 (estimated)
NCT05887492Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsPhase 1/Phase 2Active, not recruitingJun 12, 20232026-09 (estimated)
NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPhase 1/Phase 2RecruitingMay 31, 20252027-06 (estimated)
NCT05275478Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsPhase 1/Phase 2TerminatedMar 23, 2022Dec 30, 2025 (actual)
NCT06810544Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossPhase 1/Phase 2RecruitingMar 24, 2025Mar 31, 2027 (estimated)
NCT06065059Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsPhase 1/Phase 2TerminatedDec 8, 2023May 22, 2024 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback